<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02516527</url>
  </required_header>
  <id_info>
    <org_study_id>CA184-247</org_study_id>
    <nct_id>NCT02516527</nct_id>
  </id_info>
  <brief_title>A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether ipilimumab is effective in the treatment of
      select advanced (unresectable, metastatic, or recurrent) solid tumors in Chinese subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 16, 2015</start_date>
  <completion_date type="Actual">September 20, 2018</completion_date>
  <primary_completion_date type="Actual">September 20, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety of ipilimumab measured by the occurrence of adverse events, serious adverse events, adverse events leading to discontinuation and deaths</measure>
    <time_frame>Up to 90 days post discontinuation of dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The tolerability of ipilimumab measured by the occurrence of adverse events, serious adverse events, adverse events leading to discontinuation and deaths</measure>
    <time_frame>Up to 90 days post discontinuation of dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Identify dose limiting toxicities in Chinese subjects with select advanced (unresectable, metastatic, or recurrent) solid tumors measured by the occurrence of adverse events, serious adverse events, adverse events leading to discontinuation, and deaths</measure>
    <time_frame>Up to 90 days post discontinuation of dosing</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Induction Phase:Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ipilimumab dose as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance Phase:Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ipilimumab dose as specified</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <arm_group_label>Induction Phase:Ipilimumab</arm_group_label>
    <arm_group_label>Maintenance Phase:Ipilimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com.

        Inclusion Criteria:

          -  Subjects with the following advanced solid tumors; metastatic or recurrent

          -  Must have measurable/non-measurable lesion per Response Evaluation Criteria in Solid
             Tumors (RECIST v1.1) criteria.

          -  Subjects have ability to comply with treatment, procedures and pharmacokinetics (PK)
             sample collection and the required study follow-up

          -  Chinese women and men, ages 18 years or older

        Exclusion Criteria:

          -  Subjects with brain metastases are excluded unless clinically stable for more than 4
             weeks at the time of randomization as determined by the investigator

          -  Subjects with ocular melanoma are excluded

          -  Any other malignancy from which the subject has been free of disease for less than two
             years, with the exception of adequately treated and cured basal or squamous cell skin
             cancer, superficial bladder cancer, or carcinoma in situ of the cervix

          -  History of, or currently active, autoimmune diseases, including but not limited to
             inflammatory bowel disease, rheumatoid arthritis, autoimmune hepatitis, systemic
             sclerosis (scleroderma and variants), systemic lupus erythematosus, autoimmune
             vasculitis, autoimmune neuropathies (eg, Guillain-Barre syndrome). Vitiligo is not
             excluded

          -  Any current or history of immunodeficiency, splenectomy, or splenic radiation

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 3, 2015</study_first_submitted>
  <study_first_submitted_qc>August 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2015</study_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

